{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:44:31Z","timestamp":1792320271655,"version":"4.4.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07736-8","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:56:04Z","timestamp":1770393364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting GLP1 receptor for reducing global cardiovascular risk"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-4436","authenticated-orcid":false,"given":"Antonio","family":"Curcio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Meringolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Marincolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Polimeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"6065","key":"7736_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/321075a0","volume":"321","author":"RA Dixon","year":"1986","unstructured":"Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature. 1986;321(6065):75\u201379.","journal-title":"Nature"},{"issue":"6323","key":"7736_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/351230a0","volume":"351","author":"K Sasaki","year":"1991","unstructured":"Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991;351(6323):230\u201333.","journal-title":"Nature"},{"issue":"18","key":"7736_CR3","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","volume":"89","author":"B Thorens","year":"1992","unstructured":"Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992;89(18):8641\u201345.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"7736_CR4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/cells13201674","volume":"13","author":"W Parichatikanond","year":"2024","unstructured":"Parichatikanond W, Duangrat R, Kurose H, Mangmool S. Regulation of \u03b2-adrenergic receptors in the heart: a review on emerging therapeutic strategies for heart failure. Cells. 2024;13(20):1674.","journal-title":"Cells"},{"issue":"Pt A","key":"7736_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.phrs.2017.05.008","volume":"125","author":"T Kawai","year":"2017","unstructured":"Kawai T, Forrester SJ, O\u2019Brien S, Baggett A, Rizzo V, Eguchi S. AT1 receptor signaling pathways in the cardiovascular system. Pharmacol Res. 2017;125(Pt A):4\u201313.","journal-title":"Pharmacol Res"},{"issue":"6868","key":"7736_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/415206a","volume":"415","author":"HA Rockman","year":"2002","unstructured":"Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415(6868):206\u201312.","journal-title":"Nature"},{"issue":"4","key":"7736_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"4","key":"7736_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, et al. GLP-1 receptor expression within the human heart. Endocrinology. 2018;159(4):1570\u201384.","journal-title":"Endocrinology"},{"issue":"1","key":"7736_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4062\/biomolther.2016.128","volume":"25","author":"S Mangmool","year":"2017","unstructured":"Mangmool S, Denkaew T, Parichatikanond W, Kurose H. \u03b2-adrenergic receptor and insulin resistance in the heart. Biomol Ther (Seoul). 2017;25(1):44\u201356.","journal-title":"Biomol Ther (Seoul)"},{"issue":"4","key":"7736_CR10","doi-asserted-by":"publisher","first-page":"H1754","DOI":"10.1152\/ajpheart.01199.2005","volume":"291","author":"A Curcio","year":"2006","unstructured":"Curcio A, Noma T, Naga Prasad SV, Wolf MJ, Lemaire A, Perrino C, et al. Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. Am J Physiol Heart Circ Physiol. 2006;291(4):H1754\u201360.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7736_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1146\/annurev.biochem.67.1.653","volume":"67","author":"JA Pitcher","year":"1998","unstructured":"Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem. 1998;67:653\u201392.","journal-title":"Annu Rev Biochem"},{"issue":"52","key":"7736_CR12","doi-asserted-by":"publisher","first-page":"15126","DOI":"10.1073\/pnas.1611023114","volume":"113","author":"LA Grisanti","year":"2016","unstructured":"Grisanti LA, Traynham CJ, Repas AA, Gao E, Koch WJ, Tilley DG. \u03b22-adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury. Proc Natl Acad Sci U S A. 2016;113(52):15126\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"7736_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1530\/JME-15-0155","volume":"55","author":"Y Ying","year":"2015","unstructured":"Ying Y, Zhu H, Liang Z, Ma X, Li S. GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt\/GSK3b\/b-catenin pathway. J Mol Endocrinol. 2015;55(3):245\u201362.","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"7736_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1253\/circj.CJ-08-0734","volume":"72","author":"PA Patel","year":"2008","unstructured":"Patel PA, Tilley DG, Rockman HA. Beta-arrestin-mediated signaling in the heart. Circ J. 2008;72(11):1725\u201329.","journal-title":"Circ J"},{"issue":"6","key":"7736_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.yjmcc.2006.07.019","volume":"41","author":"H Takenaka","year":"2006","unstructured":"Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol. 2006;41(6):989\u201397.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"7736_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","volume":"29","author":"LH Zhang","year":"2015","unstructured":"Zhang LH, Pang XF, Bai F, Wang NP, Shah AI, McKallip RJ, et al. Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1\/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther. 2015;29(3):243\u201355.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"7736_CR17","first-page":"1906","volume":"56","author":"H Miyazaki","year":"1998","unstructured":"Miyazaki H, Shibata T, Fujii N. Intracellular signaling pathways of angiotensin II receptor type 1 involved in the development of cardiovascular diseases. Nihon Rinsho. 1998;56(7):1906\u201311.","journal-title":"Nihon Rinsho"},{"issue":"1","key":"7736_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"AK Bose","year":"2005","unstructured":"Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes. 2005;54(1):146\u201351.","journal-title":"Diabetes"},{"issue":"6","key":"7736_CR19","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"T Nystr\u00f6m","year":"2004","unstructured":"Nystr\u00f6m T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahr\u00e9n B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209\u201315.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"7736_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12967-014-0327-6","volume":"12","author":"Z Lu","year":"2014","unstructured":"Lu Z, Du Sert NP, Chan SW, Yeung C-K, Lin G, Yew DTW, et al. Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. J Transl Med. 2014;12:327.","journal-title":"J Transl Med"},{"issue":"1","key":"7736_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"7736_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","volume":"20","author":"S Ansari","year":"2024","unstructured":"Ansari S, Khoo B, Tan T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20(8):447\u201359.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"7736_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/ehjcvp\/pvaf037","volume":"11","author":"A Kalayci","year":"2025","unstructured":"Kalayci A, Januzzi JL, Mitsunami M, Tanboga IH, Karabay CY, Gibson CM. Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2025;11(6):552\u201361.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10","key":"7736_CR24","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. STEP 5 study group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"1","key":"7736_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. SURMOUNT-4 Investigators; continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"4","key":"7736_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. LEADER steering Committee; LEADER trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"7736_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","volume":"23","author":"F Taktaz","year":"2024","unstructured":"Taktaz F, Fontanella RA, Scisciola L, Pesapane A, Basilicata MG, Ghosh P, et al. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc Diabetol. 2024;23(1):242.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"7736_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11886-023-02016-z","volume":"26","author":"J Harrington","year":"2024","unstructured":"Harrington J, Felker GM, Januzzi JL, Lam CSP, Lingvay I, Pagidipati NJ, et al. Worth their weight? An update on new and emerging pharmacologic agents for obesity and their potential role for persons with cardiac conditions. Curr Cardiol Rep. 2024;26(3):61\u201371.","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"7736_CR29","first-page":"e65707","volume":"16","author":"AJ Acosta G","year":"2024","unstructured":"Acosta G AJ, Chitneni E, Manzanares Vidals CJ, Modumudi S, Hammad S, et al. A comprehensive review of emerging therapies for type 2 diabetes and their cardiovascular effects. Cureus. 2024;16(7):e65707.","journal-title":"Cureus"},{"key":"7736_CR30","doi-asserted-by":"crossref","unstructured":"Palani A, Patel S, Patel S, Srivastava S, Patel J, Salehin S, et al. GLP1-RA and SGLT2-i: implementation and insulin deescalation strategies. Cardiovasc Drugs Ther. 2025.","DOI":"10.1007\/s10557-025-07744-8"},{"issue":"9","key":"7736_CR31","first-page":"e68786","volume":"16","author":"N Fatima","year":"2024","unstructured":"Fatima N, Anand A, Palvia AR, Kaur A, Azeez GA, Thirunagari M, et al. Efficacy of different doses and forms of the GLP-1 receptor agonist semaglutide in weight reduction among non-diabetic obese or overweight populations. Cureus. 2024;16(9):e68786.","journal-title":"Cureus"},{"issue":"6","key":"7736_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, et al. SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10","key":"7736_CR33","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"7736_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13098-024-01497-4","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Zhang X, Xiang X, Fang X, Feng S. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16(1):251.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"7736_CR35","doi-asserted-by":"publisher","first-page":"e240046","DOI":"10.1530\/JOE-24-0046","volume":"263","author":"N Mullur","year":"2024","unstructured":"Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024;263(1):e240046.","journal-title":"J Endocrinol"},{"issue":"11","key":"7736_CR36","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, et al. S. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail. 2024;12(11):1814\u201326.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"7736_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/HCO.0000000000001113","volume":"39","author":"R Verma","year":"2024","unstructured":"Verma R, Dhingra NK, Connelly KA. Obesity\/Cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials. Curr Opin Cardiol. 2024;39(2):92\u201397.","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"7736_CR38","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1186\/s12967-025-06976-4","volume":"23","author":"M Anselme","year":"2025","unstructured":"Anselme M, He H, Lai C, Luo W, Zhong S. Targeting mitochondrial transporters and metabolic reprogramming for disease treatment. J Transl Med. 2025;23(1):1111.","journal-title":"J Transl Med"},{"key":"7736_CR39","doi-asserted-by":"publisher","first-page":"105052","DOI":"10.1016\/j.phrs.2020.105052","volume":"160","author":"C Berra","year":"2020","unstructured":"Berra C, Manfrini R, Regazzoli D, Radaelli MG, Disoteo O, Sommese C, et al. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacol Res. 2020;160:105052.","journal-title":"Pharmacol Res"},{"issue":"3","key":"7736_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s13679-024-00580-1","volume":"13","author":"K Sweatt","year":"2024","unstructured":"Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep. 2024;13(3):584\u201395.","journal-title":"Curr Obes Rep"},{"key":"7736_CR41","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"5","author":"XH Pan","year":"2024","unstructured":"Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obes (Silver Spring). 2024;5:840\u201356.","journal-title":"Obes (Silver Spring)"},{"issue":"1","key":"7736_CR42","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13098-025-01917-z","volume":"17","author":"W Zheng","year":"2025","unstructured":"Zheng W, Qi Q, Li J, He C, Fan H. Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies. Diabetol Metab Syndr. 2025;17(1):336.","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"7736_CR43","first-page":"145","volume":"11","author":"F Natale","year":"2024","unstructured":"Natale F, Luisi E, Franzese R, Mollo N, Solimene A, Caso VM, et al. Semaglutide in cardiometabolic diseases: SELECTing the target population. J Cardiovasc Dev Dis. 2024;11(5):145.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"7736_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/cells13010065","volume":"13","author":"SS Wilbon","year":"2023","unstructured":"Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. 2023;13(1):65.","journal-title":"Cells"},{"issue":"3","key":"7736_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40119-025-00426-4","volume":"14","author":"N Gupta","year":"2025","unstructured":"Gupta N, Zayyad Z, Bhattaram R, Tiu D, Dau J, Guburxani V, et al. Beyond blood sugar: a scoping review of GLP-1 receptor agonists in cardiovascular care. Cardiol Ther. 2025;14(3):351\u201366.","journal-title":"Cardiol Ther"},{"issue":"8","key":"7736_CR46","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19(8):460\u201376.","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"7736_CR47","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl, 5","key":"7736_CR48","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.jcjd.2015.10.001","volume":"39","author":"DC Lau","year":"2015","unstructured":"Lau DC, Teoh H. Current and emerging pharmacotherapies for weight management in prediabetes and diabetes. Can J Diabetes. 2015;39(Suppl, 5):S134\u201341.","journal-title":"Can J Diabetes"},{"issue":"11","key":"7736_CR49","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s11010-022-04474-5","volume":"477","author":"B Turan","year":"2022","unstructured":"Turan B, Durak A, Olgar Y, Tuncay E. Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction. Mol Cell Biochem. 2022;477(11):2609\u201325.","journal-title":"Mol Cell Biochem"},{"key":"7736_CR50","doi-asserted-by":"publisher","first-page":"102789","DOI":"10.1016\/j.eclinm.2024.102789","volume":"75","author":"C Jarade","year":"2024","unstructured":"Jarade C, Zolotarova T, Moiz A, Eisenberg MJ. GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review. EClinicalMedicine. 2024;75:102789.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"7736_CR51","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al. S. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326(5):H1159\u201376.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"7736_CR52","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12967-025-07005-0","volume":"23","author":"L Liu","year":"2025","unstructured":"Liu L, Zhou Y, Liu J, Zhang X, He C, Zeng X, et al. GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential. J Transl Med. 2025;23(1):960.","journal-title":"J Transl Med"},{"issue":"3","key":"7736_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2174\/1568006043336258","volume":"4","author":"A Mongiardo","year":"2004","unstructured":"Mongiardo A, Curcio A, Spaccarotella C, Parise S, Indolfi C. Molecular mechanisms of restenosis after percutaneous peripheral angioplasty and approach to endovascular therapy. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4(3):275\u201387.","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"issue":"10","key":"7736_CR54","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/biomedicines13102466","volume":"13","author":"LR Romano","year":"2025","unstructured":"Romano LR, Celeste A, Curcio A. Hormonal atrial fibrillation: pathophysiological mechanisms that trigger and sustain the arrhythmic circuits. Biomedicines. 2025;13(10):2466.","journal-title":"Biomedicines"},{"issue":"1","key":"7736_CR55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","volume":"30","author":"GB Bonfioli","year":"2025","unstructured":"Bonfioli GB, Rodella L, Metra M, Vizzardi E. GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. Heart Fail Rev. 2025;30(1):131\u201336.","journal-title":"Heart Fail Rev"},{"key":"7736_CR56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","volume":"22","author":"RA Fontanella","year":"2024","unstructured":"Fontanella RA, Ghosh P, Pesapane A, Taktaz F, Puocci A, Franzese M, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024;22:114.","journal-title":"J Transl Med"},{"key":"7736_CR57","doi-asserted-by":"publisher","first-page":"e05","DOI":"10.15420\/aer.2024.20","volume":"14","author":"LR Romano","year":"2025","unstructured":"Romano LR, Polimeni A, Indolfi C, Curcio A. Management of cardiac rhythm disorders in cardio-oncology. Arrhythm Electrophysiol Rev. 2025;14:e05.","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"5","key":"7736_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1055\/s-0040-1709527","volume":"120","author":"M Giustozzi","year":"2020","unstructured":"Giustozzi M, Curcio A, Weijs B, Field TS, Sudikas S, Katholing A, et al. Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost. 2020;120(5):847\u201356.","journal-title":"Thromb Haemost"},{"issue":"1","key":"7736_CR59","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12967-023-04607-4","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo D, Woodford R, Menzies AM, Zimmer L, Williamson A, Ramelyte E, et al. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. J Transl Med. 2023;21(1):753.","journal-title":"J Transl Med"},{"issue":"1","key":"7736_CR60","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1186\/s12967-025-07377-3","volume":"23","author":"C Boncompagni","year":"2025","unstructured":"Boncompagni C, Giacovazzi S, Perrone M, Missiroli S, Righes G, Pinton P, et al. Radiation meets inflammation: NLRP3 inflammasome at the core of radiation-induced cardiac injury. J Transl Med. 2025;23(1):1330.","journal-title":"J Transl Med"},{"issue":"20","key":"7736_CR61","doi-asserted-by":"publisher","first-page":"11299","DOI":"10.3390\/ijms252011299","volume":"25","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello V, Canale ML, Bisceglia I, Iovine M, Giordano V, Giacobbe I, et al. N. glucagon-like peptide 1 receptor agonists in cardio- oncology: pathophysiology of cardiometabolic outcomes in cancer patients. Int J Mol Sci. 2024;25(20):11299.","journal-title":"Int J Mol Sci"},{"key":"7736_CR62","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European Society for therapeutic radiology and oncology (ESTRO) and the International cardio-oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022. 2022;43(41):4229\u2013361."},{"issue":"1","key":"7736_CR63","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1186\/s12967-023-04584-8","volume":"21","author":"CS Curran","year":"2023","unstructured":"Curran CS, Kopp JB. The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease. J Transl Med. 2023;21(1):706.","journal-title":"J Transl Med"},{"issue":"1","key":"7736_CR64","doi-asserted-by":"publisher","first-page":"H176","DOI":"10.1152\/ajpheart.00058.2022","volume":"323","author":"LC Heather","year":"2022","unstructured":"Heather LC, Hafstad AD, Halade GV, Harmancey R, Mellor KM, Mishra PK, et al. Guidelines on models of diabetic heart disease. Am J Physiol Heart Circ Physiol. 2022;323(1):H176\u2013200.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"7736_CR65","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12967-025-06302-y","volume":"23","author":"R Yang","year":"2025","unstructured":"Yang R, Zhang L, Guo J, Wang N, Zhang Q, Qi Z, et al. Glucagon-like peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis. J Transl Med. 2025;23(1):389.","journal-title":"J Transl Med"},{"key":"7736_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14656566.2024.2437525","volume":"1","author":"AA El-Solh","year":"2025","unstructured":"El-Solh AA, Gould E, Aibangbee K, Jimerson T, Hartling R. Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review. Expert Opin Pharmacother. 2025;1:51\u201362.","journal-title":"Expert Opin Pharmacother"},{"key":"7736_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1479-5876-11-117","volume":"11","author":"A Storka","year":"2013","unstructured":"Storka A, Burian B, F\u00fchrlinger G, Clive B, Sun T, Crevenna R, et al. VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model. J Transl Med. 2013;11:117.","journal-title":"J Transl Med"},{"key":"7736_CR68","doi-asserted-by":"publisher","first-page":"706908","DOI":"10.3389\/fphar.2021.706908","volume":"12","author":"F Yang","year":"2021","unstructured":"Yang F, Zeng F, Luo X, Lei Y, Li J, Lu S, et al. GLP-1 receptor: a new target for sepsis. Front Pharmacol. 2021;12:706908.","journal-title":"Front Pharmacol"},{"key":"7736_CR69","doi-asserted-by":"publisher","first-page":"175730","DOI":"10.1016\/j.ejphar.2023.175730","volume":"949","author":"Y Wang","year":"2023","unstructured":"Wang Y, Deng F, Zhong X, Du Y, Fan X, Al SH. Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis. Eur J Pharmacol. 2023;949:175730.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"7736_CR70","doi-asserted-by":"publisher","first-page":"L368","DOI":"10.1152\/ajplung.00041.2023","volume":"325","author":"B Baer","year":"2023","unstructured":"Baer B, Putz ND, Riedmann K, Gonski S, Lin J, Ware LB, et al. Liraglutide pretreatment attenuates sepsis-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2023;325(3):L368\u201384.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7736_CR71","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0899-9007(02)00940-1","volume":"18","author":"BW Tobin","year":"2002","unstructured":"Tobin BW, Uchakin PN, Leeper-Woodford SK. Insulin secretion and sensitivity in space flight: diabetogenic effects. Nutrition. 2002;18:842\u201348.","journal-title":"Nutrition"},{"key":"7736_CR72","doi-asserted-by":"crossref","unstructured":"Ng VWS, Mollan SP. An eye on long-duration spaceflight: controversies, countermeasures and challenges. Exp Physiol. 2025;1\u201311.","DOI":"10.1113\/EP091561"},{"issue":"8","key":"7736_CR73","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/0026-0495(88)90018-2","volume":"37","author":"CA Stuart","year":"1988","unstructured":"Stuart CA, Shangraw RE, Prince MJ, Peters EJ, Wolfe RR. Bed-rest-induced insulin resistance occurs primarily in muscle. Metabolism. 1988;37(8):802\u201306.","journal-title":"Metabolism"},{"issue":"6 Pt 2","key":"7736_CR74","first-page":"R1739","volume":"276","author":"TP Stein","year":"1999","unstructured":"Stein TP, Leskiw MJ, Schluter MD, Hoyt RW, Lane HW, Gretebeck RE, et al. Energy expenditure and balance during spaceflight on the space shuttle. Am J Physiol. 1999;276(6 Pt 2):R1739\u201348.","journal-title":"Am J Physiol"},{"key":"7736_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphys.2017.00279","volume":"8","author":"G Gambara","year":"2017","unstructured":"Gambara G, Salanova M, Ciciliot S, Furlan S, Gutsmann M, Schiffl G, et al. Microgravity-induced transcriptome adaptation in mouse paraspinal longissimus dorsi muscle highlights insulin resistance-linked genes. Front Physiol. 2017;8:279.","journal-title":"Front Physiol"},{"issue":"1","key":"7736_CR76","doi-asserted-by":"publisher","first-page":"e13677","DOI":"10.1002\/jcsm.13677","volume":"16","author":"VJ Old","year":"2025","unstructured":"Old VJ, Davies MJ, Papamargaritis D, Choudhary P, Watson EL. The effects of glucagone-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review. J Cachexia Sarcopenia Muscle. 2025;16(1):e13677.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7736_CR77","unstructured":"Costanzo S, Curcio A, Meringolo F, Buonanno G. Combined microwave sensing-machine learning approach for non-invasive monitoring in space conditions of blood glucose concentration from reduced measurement data. 2025 IEEE Conference on Antenna Measurements and Applications (CAMA)."},{"issue":"1","key":"7736_CR78","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1186\/s12967-025-07263-y","volume":"23","author":"H Liu","year":"2025","unstructured":"Liu H, Yu S, Gao S, Liu X, Qiu C, Wang N, et al. Peroxynitrite regulates ER stress-mediated Ca2+ flux to mitochondria characterizing cardiac microvascular ischemia-reperfusion injury associated with hyperhomocysteinemia. J Transl Med. 2025;23(1):1254.","journal-title":"J Transl Med"},{"issue":"19","key":"7736_CR79","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.3390\/jcm14196758","volume":"14","author":"H-M Yang","year":"2025","unstructured":"Yang H-M. GLP-1 agonists in cardiovascular diseases: mechanisms, clinical evidence, and emerging therapies. J Clin Med. 2025;14(19):6758.","journal-title":"J Clin Med"},{"key":"7736_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, et al. SURPASS-CVOT investigators. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1\u201311.","journal-title":"Am Heart J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07736-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07736-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07736-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:04:54Z","timestamp":1773151494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07736-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7736"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07736-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"341"}}